Revitope Oncology Appoints Biotech Industry Pioneer Louis Lange to its Board of Directors
Revitope Oncology Appoints Biotech Industry Pioneer Louis Lange to its Board of Directors News provided by Share this article Share this article CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- Revitope Oncology, Inc., a biotechnology company advancing a new class of precision cancer immunotherapies, today announced the appointment of biotechnology pioneer Louis Lange, M.D., Ph.D., to its Board of Directors. "We are pleased to welcome Lou to the Revitope Board of Directors during this unprecedented time at our company as we continue to build upon the tremendous momentum established with our p...
Source: prnewswire.com